Comparative effectiveness of fish oil versus fenofibrate, gemfibrozil, and atorvastatin on lowering triglyceride levels among HIV-infected patients in routine clinical care

Journal of Acquired Immune Deficiency Syndromes

Volumn 64, Issue 3, 2013, Pages 254-260

  Muñoz, Monica A ^a,b   Liu, Wei ^a   Delaney, Joseph A C ^a,c   Brown, Elizabeth ^c   Mugavero, Michael J ^d   Mathews, W Chris ^e   Napravnik, Sonia ^f   Willig, James H ^d   Eron, Joseph J ^f   Hunt, Peter W ^g   Kahn, James O ^g   Saag, Michael S ^d   Kitahata, Mari M ^c   Crane, Heidi M ^c  

^a UNIVERSITY OF FLORIDA   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d University of Alabama at Birmingham   (United States)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

dyslipidemia; fibrates; fish oil; HIV; triglycerides

Indexed keywords

ATORVASTATIN; FENOFIBRATE; FISH OIL; GEMFIBROZIL; PROTEINASE INHIBITOR; TRIACYLGLYCEROL; ANTILIPEMIC AGENT; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; BODY MASS; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONFERENCE PAPER; DIABETES MELLITUS; EXPERIMENTAL DESIGN; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; BLOOD; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; COMPLICATION; DRUG INTERACTION; HIV INFECTIONS; HYPERTRIGLYCERIDEMIA; MIDDLE AGED; MULTICENTER STUDY; PRACTICE GUIDELINE; TREATMENT OUTCOME; UNITED STATES;

ADULT; ALABAMA; CALIFORNIA; CD4-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; COMPARATIVE EFFECTIVENESS RESEARCH; DRUG INTERACTIONS; FEMALE; FENOFIBRATE; FISH OILS; GEMFIBROZIL; HEPTANOIC ACIDS; HIV INFECTIONS; HUMANS; HYPERTRIGLYCERIDEMIA; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; NORTH CAROLINA; PRACTICE GUIDELINES AS TOPIC; PYRROLES; RETROSPECTIVE STUDIES; SAN FRANCISCO; TREATMENT OUTCOME; TRIGLYCERIDES; WASHINGTON;

EID: 84886398330     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182a60e82     Document Type: Conference Paper

References (36)

1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final report. Circulation. 2002;106:3143-3421.
2. Lorenz MW, Stephan C, Harmjanz A, et al. Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis. Atherosclerosis. 2008;196:720-726.
3. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA. 2003;289:2978-2982.
4. Hsue PY, Lo JC, Franklin A, et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation. 2004;109:1603-1608.
5. Dubé M, Stein J, Aberg J, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37:613-627.
6. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet. 1999;354:447-455.
7. Simons LA, Hickie JB, Balasubramaniam S. On the effects of dietary n-3 fatty acids (Maxepa) on plasma lipids and lipoproteins in patients with hyperlipidaemia. Atherosclerosis. 1985;54:75-88.
8. Carter VM, Woolley I, Jolley D, et al. A randomized controlled trial of omega-3 fatty acid supplementation for the treatment of hypertriglyceridemia in HIV-infected males on highly active antiretroviral therapy. Sex Health. 2006;3:287-290.
9. Wohl DA, Tien HC, Busby M, et al. Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia. Clin Infect Dis. 2005;41:1498-1504.
10. Woods MN, Wanke CA, Ling PR, et al. Effect of a dietary intervention and n-3 fatty acid supplementation on measures of serum lipid and insulin sensitivity in persons with HIV. Am J Clin Nutr. 2009;90:1566-1578.
11. Manfredi R, Calza L, Chiodo F. Polyunsaturated ethyl esters of n-3 fatty acids in HIV-infected patients with moderate hypertriglyceridemia: comparison with dietary and lifestyle changes, and fibrate therapy. J Acquir Immune Defic Syndr. 2004;36:878-880.
12. Gerber JG, Kitch DW, Fichtenbaum CJ, et al. Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186. J Acquir Immune Defic Syndr. 2008;47:459-466.
13. Kitahata M, Rodriguez B, Haubrich R, et al. Cohort profile: the Centers for AIDS Research Network of Integrated clinical Systems. Int J Epidemiol. 2008;37:948-955.
14. Delaney JA, Moodie EE, Suissa S. Validating the effects of drug treatment on blood pressure in the General Practice Research Database. Pharmacoepidemiol Drug Saf. 2008;17:535-545.
15. Ray WA. Evaluating medication effects outside of clinical trials: newuser designs. Am J Epidemiol. 2003;158:915-920.
16. Singh S, Willig JH, Mugavero MJ, et al. Comparative effectiveness and toxicity of statins among HIV-infected patients. Clin Infect Dis. 2011;52: 387-395.
17. Jackevicius CA, Tu JV, Ross JS, et al. Use of fibrates in the United States and Canada. JAMA. 2011;305:1217-1224.
18. Enger C, Gately R, Ming EE, et al. Pharmacoepidemiology safety study of fibrate and statin concomitant therapy. Am J Cardiol. 2010; 106:1594-1601.
19. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol. 2005;95:120-122.
20. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR*Trial). Am J Cardiol. 2003;92:152-160.
21. Townsend ML, Hollowell SB, Bhalodia J, et al. A comparison of the effectiveness of lipid-lowering therapy between HIV- and non-HIV-infected subjects with hyperlipidaemia. Int J STD AIDS. 2007;18:851-855.
22. Silverberg MJ, Leyden W, Hurley L, et al. Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection. Ann Intern Med. 2009;150:301-313.
23. McKenney JM, Swearingen D, Di Spirito M, et al. Study of the pharmacokinetic interaction between simvastatin and prescription omega-3-acid ethyl esters. J Clin Pharmacol. 2006;46:785-791.
24. Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010;375:1875-1884.
25. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005; 366:1849-1861.
26. Frick MH, Elo O, Haapa K, et al. Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237-1245.
27. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341:410-418.
28. Lee JH, O'Keefe JH, Lavie CJ, et al. Omega-3 fatty acids for cardioprotection. Mayo Clin Proc. 2008;83:324-332.
29. Marik PE, Varon J. Omega-3 dietary supplements and the risk of cardiovascular events: a systematic review. Clin Cardiol. 2009;32:365-372.
30. Oliveira JM, Rondó PH. Omega-3 fatty acids and hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: systematic review and meta-analysis. HIV Clin Trials. 2011;12:268-274.
31. Ginsberg HN. Effects of statins on triglyceride metabolism. Am J Cardiol. 1998;81:32B-35B.
32. Farnier M, Salko T, Isaacsohn JL, et al. Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil). Am J Cardiol. 2003; 92:794-797.
33. Nordestgaard BG, Benn M, Schnohr P, et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298:299-308.
34. Busse KH, Hadigan C, Chairez C, et al. Gemfibrozil concentrations are significantly decreased in the presence of lopinavir-ritonavir. J Acquir Immune Defic Syndr. 2009;52:235-239.
35. Willig JH, Jackson DA, Westfall AO, et al. Clinical inertia in the management of low-density lipoprotein abnormalities in an HIV clinic. Clin Infect Dis. 2008;46:1315-1318.
36. Oelrich B, Dewell A, Gardner CD. Effect of fish oil supplementation on serum triglycerides, LDL cholesterol and LDL subfractions in hypertriglyceridemic adults. Nutr Metab Cardiovasc Dis. 2013;23:350-357.